US · ORIC · BIOTECHNOLOGY
ORIC Pharmaceuticals, Inc. (ORIC) intrinsic value and stock valuation
$7.36as of 2026-11-21 · Mkt cap 1.4B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
ORIC Pharmaceuticals, Inc. DCF and intrinsic value
InvestorsCraft values ORIC with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ORIC’s statements →
ORIC Pharmaceuticals, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2017–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating income | -$-143M | -$-142.9M | -$-110.78M | -$-91.77M | -$-78.87M |
| Net income | -$-129.47M | -$-127.85M | -$-100.7M | -$-89.12M | -$-78.72M |
| EPSd | -$-1.47M | -$-1.83M | -$-1.96M | -$-2.25M | -$-2.07M |
| Operating cash flow | -$-113.37M | -$-112.66M | -$-85.69M | -$-75.14M | -$-59.54M |
| Capital expenditure | -$-710K | -$-1.19M | -$-850K | -$-2.08M | -$-940K |
| Free cash flow | -$-114.08M | -$-113.85M | -$-86.54M | -$-77.22M | -$-60.48M |
| Total assets | $411M | $274.1M | $254.7M | $250.4M | $298.6M |
| Total debt | $11.6M | $3.18M | $10.2M | $12.1M | $1.93M |
| Net debt | -$-34.12M | -$-56.22M | -$-13.17M | -$-54.74M | -$-224.08M |
| Total equity | $384.4M | $243.1M | $224.1M | $222.4M | $273M |
| Cash and short-term investments | $281.5M | $256M | $208.2M | $206.3M | $237M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $1.22M | $1.11M | $1.03M | $0.00 | $0.00 |
| Gross profit | -$-1.22M | -$-1.11M | -$-1.03M | $0.00 | $0.00 |
| Research and development expenses | $109.8M | $114.1M | $85.2M | $61.7M | $56.9M |
| Selling, general and administrative expenses | $33.2M | $28.8M | $25.6M | $25.1M | $22M |
| Other expenses | -$-1.22M | -$-1.11M | -$-1.03M | $5M | $0.00 |
| Operating expenses | $141.8M | $141.8M | $109.8M | $91.8M | $78.9M |
| Cost and expenses | $143M | $142.9M | $110.8M | $91.8M | $78.9M |
| Interest income | $0.00 | $0.00 | $10.1M | $2.65M | $140K |
| Interest expense | $0.00 | $0.00 | $0.00 | $2.65M | $0.00 |
| Depreciation and amortization | $1.22M | $1.11M | $1.03M | $970K | $900K |
| Ebitda | -$-128.25M | -$-126.74M | -$-99.67M | -$-85.8M | -$-77.82M |
| Operating income | -$-143M | -$-142.9M | -$-110.78M | -$-91.77M | -$-78.87M |
| Total other income/expenses, net | $13.5M | $15.1M | $10.1M | $2.65M | $160K |
| Income before tax | -$-129.47M | -$-127.85M | -$-100.7M | -$-89.12M | -$-78.72M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-129.47M | -$-127.85M | -$-100.7M | -$-89.12M | -$-78.72M |
| Weighted average shares outstanding | $87.8M | $69.7M | $51.5M | $39.7M | $38M |
| Weighted average diluted shares outstanding | $87.8M | $69.7M | $51.5M | $39.7M | $38M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $281.5M | $256M | $208.2M | $206.3M | $237M |
| Net receivables | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $288.5M | $262.3M | $212.6M | $210.5M | $240.5M |
| Property, plant and equipment, net | $9.07M | $2.92M | $12M | $14.3M | $2.41M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $111.3M | $0.00 | $27.3M | $22.4M | $43.4M |
| Total non-current assets | $122.5M | $11.9M | $42.1M | $39.9M | $58.1M |
| Total assets | $411M | $274.1M | $254.7M | $250.4M | $298.6M |
| Accounts payable | $3.82M | $1.55M | $940K | $1.32M | $1.89M |
| Short-term debt | $3.33M | $3.18M | $2.75M | $2.66M | $1.93M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $20.4M | $24.9M | $20.5M | $15.4M | $15.2M |
| Long-term debt | $8.22M | $0.00 | $7.46M | $9.44M | $0.00 |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $6.22M | $6.17M | $10.1M | $12.6M | $10.5M |
| Capital lease obligations | $4.11M | $3.18M | $7.46M | $9.44M | $1.93M |
| Total liabilities | $26.6M | $31M | $30.6M | $28M | $25.7M |
| Common stock | $10K | $10K | $10K | $10K | $0.00 |
| Retained earnings | -$-692.24M | -$-562.77M | -$-434.93M | -$-334.23M | -$-245.11M |
| Accumulated other comprehensive income (loss) | $790K | $380K | $260K | -$-1.29M | -$-100K |
| Total equity | $384.4M | $243.1M | $224.1M | $222.4M | $273M |
| Total investments | $346.6M | $196.6M | $212.2M | $161.9M | $54.4M |
| Total debt | $11.6M | $3.18M | $10.2M | $12.1M | $1.93M |
| Net debt | -$-34.12M | -$-56.22M | -$-13.17M | -$-54.74M | -$-224.08M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-129.47M | -$-127.85M | -$-100.7M | -$-89.12M | -$-78.72M |
| Depreciation and amortization | $1.22M | $1.11M | $1.03M | $970K | $900K |
| Stock-based compensation | $0.00 | $20.2M | $15.2M | $14.5M | $12.9M |
| Change in working capital | -$-5.46M | $1.97M | $4.9M | -$-450K | $4.07M |
| Accounts receivable | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | -$-7.25M | $1.82M | $0.00 | -$-1.48M | $2.93M |
| Net cash provided by operating activities | -$-113.37M | -$-112.66M | -$-85.69M | -$-75.14M | -$-59.54M |
| Investments in property, plant and equipment | -$-710K | -$-1.19M | -$-850K | -$-2.08M | -$-940K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $2.08M | $1.38M |
| Net cash used for investing activities | -$-148.03M | $22.1M | -$-43.4M | -$-109.25M | $158.4M |
| Common stock issued | $247.7M | $125M | $85M | $25M | $50M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $247.7M | $126.6M | $85.7M | $25.2M | $49.1M |
| Net change in cash | -$-13.74M | $36M | -$-43.43M | -$-159.17M | $148M |
| Cash at end of period | $46.2M | $59.9M | $23.9M | $67.3M | $226.5M |
| Operating cash flow | -$-113.37M | -$-112.66M | -$-85.69M | -$-75.14M | -$-59.54M |
| Capital expenditure | -$-710K | -$-1.19M | -$-850K | -$-2.08M | -$-940K |
| Free cash flow | -$-114.08M | -$-113.85M | -$-86.54M | -$-77.22M | -$-60.48M |
Line items
Line items
Line items
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.
- CEO
- Jacob Chacko
- Employees
- 104
- Beta
- 1.01
Explore
Frequently asked questions
What is the intrinsic value of ORIC Pharmaceuticals, Inc. (ORIC)?
InvestorsCraft does not currently publish an intrinsic value for ORIC. How the IC value is calculated.
Is ORIC undervalued?
InvestorsCraft does not publish an undervaluation signal for ORIC at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.